Stonepine Capital Management LLC decreased its holdings in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 1.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 222,321 shares of the company’s stock after selling 3,556 shares during the period. Oxford Immunotec Global comprises about 2.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 15th largest holding. Stonepine Capital Management LLC’s holdings in Oxford Immunotec Global were worth $2,841,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Engineers Gate Manager LP purchased a new stake in Oxford Immunotec Global in the third quarter worth $188,000. Trexquant Investment LP purchased a new position in Oxford Immunotec Global during the third quarter valued at $279,000. Rhumbline Advisers lifted its position in Oxford Immunotec Global by 50.7% during the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock valued at $419,000 after buying an additional 11,022 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Oxford Immunotec Global during the third quarter valued at $445,000. Finally, Hound Partners LLC purchased a new position in Oxford Immunotec Global during the third quarter valued at $524,000. 91.12% of the stock is owned by institutional investors.
Oxford Immunotec Global stock traded up $0.50 on Monday, hitting $16.26. 1,352 shares of the stock traded hands, compared to its average volume of 124,209. The firm has a market capitalization of $415.45 million, a P/E ratio of -11.88 and a beta of 0.33. Oxford Immunotec Global PLC has a 1 year low of $11.66 and a 1 year high of $19.19.
In other news, SVP Elizabeth M. Keiley sold 4,100 shares of Oxford Immunotec Global stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $17.00, for a total value of $69,700.00. Following the completion of the transaction, the senior vice president now owns 26,928 shares of the company’s stock, valued at approximately $457,776. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 10,000 shares of Oxford Immunotec Global stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the transaction, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,100 shares of company stock valued at $431,450. 6.61% of the stock is owned by insiders.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Further Reading: Hedge Funds
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.